FDA expands Auvelity use to Alzheimer’s-related agitation
Bottom line
Axsome Therapeutics said the US Food and Drug Administration approved an expanded indication for Auvelity to treat agitation associated with dementia due to Alzheimer’s disease in adults on April 30, 2026. That makes Auvelity the first FDA-approved non-antipsychotic for this use, and the second approved drug overall after Rexulti’s 2023 approval. Auvelity, a dextromethorphan-bupropion combination first cleared in 2022 for major depressive disorder, now carries labeling that includes a scheduled titration for Alzheimer’s-related agitation and notes that it isn’t intended for as-needed use. (fda.gov)
Why it matters: While this is a human drug development, it’s still relevant to veterinary professionals tracking neurobehavioral therapeutics, caregiver burden, and the broader CNS drug pipeline. The approval adds a mechanistically distinct option in a space long dominated by off-label approaches and antipsychotic risk-benefit debates. FDA said the decision was supported by two randomized trials, and the updated label lists dizziness and dyspepsia among the most common adverse reactions in the Alzheimer’s agitation population. Alzheimer’s Association leaders also emphasized that medication should complement, not replace, first-line non-pharmacologic strategies and individualized care planning. (fda.gov)
What to watch: Watch for launch uptake, payer coverage, and how clinicians position Auvelity alongside non-drug interventions and existing use of Rexulti. (fda.gov)
Axsome Therapeutics has won FDA approval for Auvelity as a treatment for agitation associated with dementia due to Alzheimer’s disease in adults, expanding the drug beyond its original 2022 indication in major depressive disorder. The April 30, 2026 decision gives the market its first FDA-approved non-antipsychotic option for Alzheimer’s agitation, a clinically difficult symptom cluster that can include restlessness, verbal aggression, and physical aggression. (fda.gov)
The approval lands in a category that only recently gained any FDA-cleared therapies. In May 2023, the FDA approved Rexulti, making it the first approved treatment for agitation associated with dementia due to Alzheimer’s disease. Auvelity now becomes the second approved product in the space, but with a different pharmacologic profile, which could matter for clinicians and families weighing tolerability, mechanism, and treatment sequencing. (fda.gov)
Axsome had been building toward this decision for years. The company said the supplemental NDA was backed by a broader development program that included four randomized, double-blind, controlled Phase 3 trials and a long-term safety study, and the FDA had previously granted Breakthrough Therapy designation in June 2020 and Priority Review for the filing. In its approval announcement, Axsome described agitation as affecting up to 76% of people with Alzheimer’s disease, underscoring the size of the unmet need. (axsometherapeuticsinc.gcs-web.com)
The FDA said Auvelity showed efficacy in two randomized trials. In the first, a five-week placebo-controlled study, the primary endpoint was change in Cohen-Mansfield Agitation Inventory, or CMAI, score. The prescribing information identifies that study as enrolling patients randomized to Auvelity, placebo, or bupropion, with the bupropion arm ended early for futility. The updated label also sets out a specific titration schedule for Alzheimer’s agitation, beginning once daily and increasing based on tolerability, while stating the drug isn’t indicated for PRN use. Common adverse reactions in this population were dizziness and dyspepsia, and the label calls for blood pressure assessment and periodic monitoring. (fda.gov)
Outside the company, early reaction has been cautiously positive. The Alzheimer’s Association welcomed the approval and called Auvelity the first non-antipsychotic treatment specifically approved for Alzheimer’s disease agitation, while reiterating that non-pharmacologic strategies such as environmental changes, structured routines, and psychosocial interventions should remain first-line. In Psychiatric Times, geriatric psychiatrist Rajesh R. Tampi said the approval is welcome but urged clinicians to prescribe thoughtfully and involve family members in treatment planning, highlighting that real-world use will still require careful patient selection. (alz.org)
Why it matters: For veterinary professionals, this is mainly a signal story rather than a practice-change story. It reflects continued investment in neurobehavioral therapeutics, growing regulatory openness to symptom-focused CNS indications, and the commercial value of treatments aimed at distressing caregiver-observed behaviors. It also reinforces a familiar clinical lesson: behavior-focused drugs may gain traction fastest when they’re paired with structured environmental and caregiving interventions, not positioned as stand-alone fixes. (alz.org)
There are still open questions. Auvelity enters a market where Rexulti already has a foothold, and uptake will likely depend on comparative prescribing comfort, reimbursement, and how clinicians interpret the non-antipsychotic positioning against the product’s warnings and monitoring requirements. The next phase to watch is commercialization: payer access, real-world tolerability, and whether specialists and geriatric prescribers see Auvelity as an earlier option or a later alternative after behavioral strategies and other medicines. (accessdata.fda.gov)